Personal genomics company 23andMe has partnered with pharmaceutical giant Pfizer to explore possible genetic factors associated with Inflammatory Bowel Disease, a chronic illness that affects some 1.4 million people in the United States. The companies plan to enroll and analyze the genomes of 10,000 people diagnosed with Crohn’s disease or ulcerative colitis. “We are excited to team up with Pfizer to take an innovative, consumer-centered approach to try to understand the fundamentals of inflammatory bowel disease and the variability of treatment response,” 23andMe CEO Anne Wojcicki said in a statement. Read more about the study here.
More in Technology


AI isn’t going to be the end of the world — no matter what this documentary sometimes argues.


The AI company released a set of highly progressive policy ideas. There’s just one small problem.


Protecting astronauts in space — and maybe even Mars — will help transform health on Earth.


Houston, we have a plumbing problem.


How they’re using AI at the lab that created the atom bomb.


Space barons like Jeff Bezos and Elon Musk don’t seem religious. But their quest to colonize outer space is.